Controlling glycaemic variables with pioglitazone prior to and during therapy with peginterferon alfa-2a + ribavirin does not improve early virological response in patients with chronic genotype 1 hepatitis C

Trial Profile

Controlling glycaemic variables with pioglitazone prior to and during therapy with peginterferon alfa-2a + ribavirin does not improve early virological response in patients with chronic genotype 1 hepatitis C

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2012

At a glance

  • Drugs Peginterferon alfa-2a; Pioglitazone; Ribavirin
  • Indications Hepatitis C; Insulin resistance
  • Focus Therapeutic Use
  • Acronyms SENSITIZE
  • Most Recent Events

    • 15 Feb 2012 Results published in the Hepatology.
    • 08 Nov 2011 Results including 72 week data presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
    • 04 Nov 2011 Primary endpoint 'Early-virological-response-rate' has not been met (3063700) as reported by result presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top